Mercaptopurine Anhydrous

Mercaptopurine Anhydrous

SCHEMBL9952688

Nc1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)n1.Sc1ncnc2nc[nH]c12

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPAT

The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.37
PDE4D Q08499 1/20 0.37
SLC29A1 Q99808 1/20 0.37
LMNA P02545 3/20 0.35
THRB P10828 1/20 0.35
MTOR P42345 1/20 0.35
MDM2 Q00987 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
CACNA1F O60840 2/20 0.30
ALB P02768 2/20 0.30
MAPT P10636 2/20 0.30
CACNA1D Q01668 2/20 0.30
CACNA1S Q13698 2/20 0.30
CACNA1C Q13936 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51650 0.84 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL27544566 0.84 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
Pyrimidine SCHEMBL7857437 0.79 PDE3A (0.41) PDE3APDE4DSLC29A1LMNATHRB
Adenine SCHEMBL14639108 0.73 LMNA (0.39) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL4971926 0.72 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL3424602 0.71 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL1939478 0.71 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL28379714 0.71 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL1962181 0.70 PDE3A (0.45) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL7794942 0.70 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2654779-A1 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF Ludwig Institute for Cancer Research, Ltd. (US) 2013-10-30 EP disclosed
WO-2012088414-A1 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2012-06-28 WO disclosed